1. Introduction {#sec1-marinedrugs-17-00584}
===============

Secondary metabolites played a vital role in discovery and development of drugs and saved the lives of millions of people over the past decades \[[@B1-marinedrugs-17-00584],[@B2-marinedrugs-17-00584]\]. Microbial secondary metabolites contributed significantly to drug discovery and pharmaceutical industry. There is a continuous need for novel chemical entities with new mechanisms of action to overcome drug resistance and to fulfill the medical needs for new drugs \[[@B3-marinedrugs-17-00584]\]. This need forced the chemists to search for understudied microbial resources that inhabit challenging environments \[[@B4-marinedrugs-17-00584]\]. The marine environment, with its great biological diversity, has been considered as under-investigated source of microbes with unlimited biosynthetic capabilities for bioactive compounds \[[@B4-marinedrugs-17-00584]\]. Marine actinobateria, including actinomycetes, have proven to be producers of novel chemical entities with diverse bioactivities such as antitumor, antimicrobial, anti-inflammatory, antiparasitic, antimalarial, antiviral, antioxidant, anti-angiogenesis and many others \[[@B5-marinedrugs-17-00584],[@B6-marinedrugs-17-00584]\]. The 2,5-diketopiperazines (DKPs) belong to the smallest cyclic dipeptides that consist of a six-membered ring containing two amide linkages where the two nitrogen atoms and the two carbonyls are at opposite positions. DKPs are represented in structurally diverse groups of secondary metabolites, with different examples showing significant bioactivities including antimicrobial, antitumor, analgesic, and many other biomedical indications \[[@B7-marinedrugs-17-00584]\]. Prominent anticancer DKPs include the anti-microtubule phenylahistins \[[@B8-marinedrugs-17-00584]\], the cell cycle inhibitors tryprostatins \[[@B9-marinedrugs-17-00584]\], the chaetocins, which inhibit the lysine-specific histone methyltransferase \[[@B10-marinedrugs-17-00584]\] and the ardeemins with their reversal effects on multiple drug resistant (MDR) phenotype \[[@B11-marinedrugs-17-00584]\].

As a part of ongoing search on marine microbial secondary metabolites \[[@B12-marinedrugs-17-00584],[@B13-marinedrugs-17-00584],[@B14-marinedrugs-17-00584],[@B15-marinedrugs-17-00584],[@B16-marinedrugs-17-00584],[@B17-marinedrugs-17-00584]\], the ethyl acetate extract of the sponge-derived *Streptomyces* species Call-36 was studied. A new diketopiperazine alkaloid with a hydroperoxy group at C-2 of the proline moiety, actinozine A (**1**), cyclo(2-OH-Pro-[l]{.smallcaps}-Leu) (**2**) \[[@B18-marinedrugs-17-00584]\], two new nucleoside derivatives, thymidine-3-mercaptocarbamic acid (**3**) and thymidine-3-thioamine (**4**), in addition to the previously reported compounds cyclo([d]{.smallcaps}-Pro-[l]{.smallcaps}-Phe) (**5**) \[[@B19-marinedrugs-17-00584]\] and cyclo([l]{.smallcaps}-Pro-[l]{.smallcaps}-Phe) (**6**) \[[@B20-marinedrugs-17-00584]\] ([Figure 1](#marinedrugs-17-00584-f001){ref-type="fig"}) were isolated. The structure assignments of the compounds were supported by comprehensive investigations of the NMR and MS data. The relative configuration of **1** and **2** was determined using the DP4 probability approach. The absolute configuration of the amino acid moieties in **1** and **2** were established by Marfey's method and by comparison of both experimental and predicted ECD spectra. In this paper, the structure determinations as well as the cytotoxic and antimicrobial activities of the compounds are discussed.

2. Results and Discussion {#sec2-marinedrugs-17-00584}
=========================

2.1. Purification of the Compounds {#sec2dot1-marinedrugs-17-00584}
----------------------------------

The ethyl acetate extract of the fermentation broth of the actinomycete, *Streptomyces* sp. Call-36, was subjected to extensive chromatographic separations over silica gel, Sephadex LH-20 and final HPLC purification to yield compounds **1**--**6**.

2.2. Structure Elucidation of the Compounds {#sec2dot2-marinedrugs-17-00584}
-------------------------------------------

Compound **1** ([Figure 1](#marinedrugs-17-00584-f001){ref-type="fig"}) was isolated as a colorless solid with molecular formula C~11~H~18~N~2~O~4~. The NMR spectra of **1** ([Figures S1--S6](#app1-marinedrugs-17-00584){ref-type="app"} and [Table 1](#marinedrugs-17-00584-t001){ref-type="table"}) displayed 11 signals including two methyls, four methylenes, two methines, and three quaternary carbons (two carbonyls and one oxygenated carbon) as supported by the ^13^C NMR and HSQC experiments ([Table 1](#marinedrugs-17-00584-t001){ref-type="table"}). The ^1^H and ^13^C NMR spectra of **1** ([Figures S1 and S2](#app1-marinedrugs-17-00584){ref-type="app"} and [Table 1](#marinedrugs-17-00584-t001){ref-type="table"}) displayed characteristic signals for a diketopiperazine ring, which included two amidic carbonyls at δ~C~ 168.0 (qC, C-2) and 167.2 (qC, C-5), a methine signal at δ~H~/δ~C~ 4.04 (dt, 7.2, 3.0 Hz, H-3)/56.0 (CH, C-3) and an amidic singlet at δ~H~ 6.25 (1H, brs, NH). In addition, the remaining ^1^H and ^13^C signals of **1** supported the presence of leucine and 2-substituted proline units. The presence of ^1^H-^1^H spin-spin coupling system in the COSY experiment of **1** ([Figure S4](#app1-marinedrugs-17-00584){ref-type="app"}) from H~2~-7 to H~2~-9 supported this assignment ([Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"}). The interruption of the coupling system at C-6 suggested its quaternary nature. The NMR signals at δ~H~/δ~C~ 167.2 (qC, C-5), 95.5 (qC, C-6), 2.44, 2.15 (H~2~-7)/33.4 (CH~2~, C-7), 2.16, 2.08 (H~2~-8)/19.2 (CH~2~, C-8), and 3.90, 3.62 (H~2~-9)/45.3 (CH~2~, C-9) are characteristic for a 2-substituted proline residue. In addition, the presence of a leucine unit was supported from the NMR signals at δ~H~/δ~C~ 168.0 (qC, C-2), 4.04 (H-3)/56.0 (CH, C-3), 6.25 (4-NH), 1.96, 1.84 (H~2~-10)/44.1 (CH~2~, C-10), 1.80 (H-11)/24.5 (C-11), 0.99 (H~3~-12)/23.1 (C-12) and 0.95 (H~3~-13)/21.1 (C-13). Again, the presence of a second ^1^H-^1^H spin-spin coupling system in the COSY experiment between H-3 and the isobutyl moiety at C-3 (H-10 → H~3~-13) supported the presence leucine unit ([Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"}). Despite the similarity between the NMR data of **1** with those of **2** ([Table 2](#marinedrugs-17-00584-t002){ref-type="table"}), there is a significant downfield shift of C-6 in **1** by 8.8 ppm (resonating at δ~C~ 95.5 instead of δ~C~ 86.7 in **2**) ([Table 2](#marinedrugs-17-00584-t002){ref-type="table"}), suggesting the presence of a hydroperoxy (OOH) (δ~H~ 9.27, brs) group at C-6 in **1** instead of OH in **2** ([Table 2](#marinedrugs-17-00584-t002){ref-type="table"}). Finally, all protonated carbons were assigned from HSQC ([Figure S6](#app1-marinedrugs-17-00584){ref-type="app"}) and COSY experiments ([Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"} and [Figure S4](#app1-marinedrugs-17-00584){ref-type="app"}), while the placement of the OOH moiety at C-6 was supported by HMBC correlations of H~2~-7/C-6 and H~2~-8/C-6 ([Table 1](#marinedrugs-17-00584-t001){ref-type="table"}, [Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"} and [Figure S6](#app1-marinedrugs-17-00584){ref-type="app"}). Similarly, the assignment of the quaternary amidic carbons (C-2 and C-5) was secured from HMBC correlations ([Table 1](#marinedrugs-17-00584-t001){ref-type="table"}, [Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"} and [Figure S6](#app1-marinedrugs-17-00584){ref-type="app"}). The relative configuration at C-6 was determined by comparison between experimental and theoretical NMR chemical shifts as proposed by Smith and Goodman \[[@B21-marinedrugs-17-00584]\] as several recent applications of this approach demonstrated to be efficient \[[@B22-marinedrugs-17-00584],[@B23-marinedrugs-17-00584]\].

As shown on [Figure 3](#marinedrugs-17-00584-f003){ref-type="fig"}, the 3S\*,6S\* relative configuration for **1b** was supported by all the metrics used. The correlation between experimental and theoretical chemical shifts was higher for **1b** (R^2^ = 0.9994) and the mean average error (MAE) value was lower for **1b** and finally a 100% DP4 score for **1b** ([Figure 3](#marinedrugs-17-00584-f003){ref-type="fig"}). All calculations for both isomers (3S,6S and 3R,6R) of **1** can be found at (<https://figshare.com/s/d626b72364548b03e11b>). The absolute configuration of the leucine residue was determined by Marfey's method \[[@B24-marinedrugs-17-00584]\]. HPLC analysis of the derivative of 1-fluoro-2,4-dinitrophenyl-5-[l]{.smallcaps}-alanine amide (FDAA, Marfey's reagent) with the hydrolytic products of **1** gave the same retention time as the derivative prepared from an authentic [l]{.smallcaps}-leucine, and therefore the [l]{.smallcaps}-configuration was assigned to the leucine residue. Due to the hydrolysis of **1** under acidic condition, the absolute configuration at C-6 was not determined by Marfey's method. The absolute configuration at C-3 and C-6 asymmetric centers was determined from analysis of the ECD spectrum of **1**. Comparison between experimental and theoretical ECD spectra gave a very good agreement as displayed on [Figure 4](#marinedrugs-17-00584-f004){ref-type="fig"}. Two Cotton effects with alternative signs were observed due to the n→π\* transition ([Figure 4](#marinedrugs-17-00584-f004){ref-type="fig"}). Thus, **1** was assigned as (3S,8aS)-8a-hydroperoxy-3-isobutylhexahydropyrrolo\[1,2-a\]pyrazine-1,4-dione {cyclo(2-OOH-[d]{.smallcaps}-Pro-[l]{.smallcaps}-Leu } and is reported here as a new natural product and named actinozine A.

Compound **2** ([Figure 1](#marinedrugs-17-00584-f001){ref-type="fig"}) was purified as colorless oil with molecular formula of C~11~H~18~N~2~O~3~. The combined one- and two-dimensional NMR data of **2** ([Table 2](#marinedrugs-17-00584-t002){ref-type="table"}, [Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"} and [Figures S8--S13](#app1-marinedrugs-17-00584){ref-type="app"}) are in good agreement with those reported for cyclo(2-OH-Pro-[l]{.smallcaps}-Leu) \[[@B18-marinedrugs-17-00584]\]. However, the absolute configuration at C-6 was missing. For the determination of the relative configuration, we followed the same approach as described above. As expected, the same 3S\* and 6S\* was obtained with a high probability (R^2^ = 0.9995) ([Figure 5](#marinedrugs-17-00584-f005){ref-type="fig"}). All calculations for both isomers (3S,6S and 3R,6R) of **2** can be found at (<https://figshare.com/s/d626b72364548b03e11b>). Again, the absolute configuration of the leucine residue was determined by Marfey's method \[[@B24-marinedrugs-17-00584]\] as discussed above and was found to be [l]{.smallcaps}-Leucine. Attempts to determine the stereochemistry at C-6 by Marfey's method was not successful because of the decomposition of **2** under acidic conditions. Therefore, a CD spectrum for compound **2** ([Figure 6](#marinedrugs-17-00584-f006){ref-type="fig"}) was recorded in order to determine the absolute configuration of the hydroxylated C-6. The absolute configuration at C-3 and C-6 in **2** was determined to be 3S and 6S by comparison of the experimental and predicted ECD spectra ([Figure 6](#marinedrugs-17-00584-f006){ref-type="fig"}). Thus, **2** was assigned as cyclo(2-OH-[d]{.smallcaps}-Pro-[l]{.smallcaps}-Leu) {(3S,8Sa)-8a-hydroxy-3-isobutylhexahydropyrrolo\[1,2-a\]pyrazine-1,4-dione}.

Compound **3** ([Figure 1](#marinedrugs-17-00584-f001){ref-type="fig"}) was isolated as a white solid with molecular formula of C~11~H~15~N~3~O~7~S as established from the HRESIMS pseudomolecular ion peak at *m/z* 334.0708 \[M + H\]^+^, suggesting six degrees of unsaturation. The ^1^H and ^13^C NMR spectrum of **3** ([Table 3](#marinedrugs-17-00584-t003){ref-type="table"} and [Figures S15 and S16](#app1-marinedrugs-17-00584){ref-type="app"}) showed signals for 2′-deoxyribose unit at δ~H~/δ~C~ 6.15 (1H, t, *J* = 7.0 Hz, H-1′)/83.7 (CH, C-1′), 2.07 (1H, m, H-2′a) and 2.02 (1H, m, 2′b)/39.5 (CH~2~, C-2′), 4.22 (1H, quin, *J* = 3.0 Hz, H-3′)/70.3 (CH, C-3′), 5.24 (1H, brs, O*H*-3′), 3.74 (1H, q, *J* = 3.5 Hz, H-4′)/87.2 (CH, C-4′) and 3.57 (1H, dd, *J* = 12.0, 3.5 Hz, H-5′a), 3.53 (1H, dd, *J* = 12.0, 4.0 Hz, H-5′b)/61.3 (CH~2~, C-5′) and 5.05 (1H, brs, O*H*-5′). This was supported by the presence of a continuous ^1^H-^1^H spin-spin coupling system in the COSY experiment ([Figure S17](#app1-marinedrugs-17-00584){ref-type="app"}) from H-2′ to H~2~-5′ ([Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"}), ^1^*J*~CH~ correlations in the HSQC experiment ([Figure S18](#app1-marinedrugs-17-00584){ref-type="app"}) and HMBC correlations ([Table 3](#marinedrugs-17-00584-t003){ref-type="table"}, [Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"} and [Figure S19](#app1-marinedrugs-17-00584){ref-type="app"}). The NMR data of the 2′-deoxyribose moiety ([Table 3](#marinedrugs-17-00584-t003){ref-type="table"}) are in good agreement with the literature \[[@B25-marinedrugs-17-00584],[@B26-marinedrugs-17-00584],[@B27-marinedrugs-17-00584]\]. In addition, the signals at δ~H/C~ 150.4 (qC, C-2), 163.7 (qC, C-4), 109.3 (qC, C-5), 7.68 (1H, s, H-6)/136.1 (CH, C-6), 1.75 (3H, s, H~3~-7)/12.2 (CH~3~, C-7) supported the presence of a substituted thymine moiety in **3** \[[@B25-marinedrugs-17-00584],[@B26-marinedrugs-17-00584]\]. Again, the COSY and HMBC correlations in **3** ([Table 3](#marinedrugs-17-00584-t003){ref-type="table"} and [Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"}) supported the presence of a thymine moiety. The remaining portion of **3** includes the elemental composition of CH~2~NO~2~S (S-NH-COOH), which corresponds to a mercaptocarbamic acid ([Figure 1](#marinedrugs-17-00584-f001){ref-type="fig"}). The existence of the mercaptocarbamic acid moiety was supported by the presence of NMR signals at δ~H/C~ 7.26 (1H, brs, N*H*) and 10.90 (1H, hump, H-3′′)/158.1 (qC, C-3′′) ([Table 3](#marinedrugs-17-00584-t003){ref-type="table"}) and by MS/MS fragmentation ion peaks at *m*/*z* 316 \[M − OH\]^+^, 288 \[M − COOH\]^+^, 273 \[M − NHCOOH\]^+^ and 242 \[M − SNHCOOH + H\]^+^ ([Figure 7](#marinedrugs-17-00584-f007){ref-type="fig"} and [Figure 8](#marinedrugs-17-00584-f008){ref-type="fig"}), completing the degrees of unsaturation and the molecular formula of **3**. The ^13^C chemical shift of the carboxylic acid moiety of the carbamic acid is in good agreement with the literature \[[@B28-marinedrugs-17-00584]\]. The placement of the 2′-desoxyribose moiety at *N*-1 was supported by HMBC long-range correlations from H-1′ to C-2 and C-6 ([Table 3](#marinedrugs-17-00584-t003){ref-type="table"} and [Figure 2](#marinedrugs-17-00584-f002){ref-type="fig"}). Since *N*-3 is the only available and free place in **3**, thus, the mercaptocarbamic acid moiety was linked to *N*-3 to complete the degrees of unsaturation and the planner structure of **3**. The strong ROESY correlation ([Figure S20](#app1-marinedrugs-17-00584){ref-type="app"}) displayed between H-1′ and H-4′ protons and the absence of any ROESY correlations between H-3′ and H-1′ as well as H-3′ and H-4′ strongly supported the *β* configuration of the nucleoside ([Table 3](#marinedrugs-17-00584-t003){ref-type="table"} and [Figure 9](#marinedrugs-17-00584-f009){ref-type="fig"}). Detailed additional and expected ROESY correlations in **3** are presented in [Table 3](#marinedrugs-17-00584-t003){ref-type="table"} and [Figure 9](#marinedrugs-17-00584-f009){ref-type="fig"}. The similarity of the value and sign of the optical rotation of **3** (+11°) with those of [d]{.smallcaps}-thymidine (+18.5°) \[[@B29-marinedrugs-17-00584]\] supported the [d]{.smallcaps}-sugar moiety in **3**. Accordingly, **3** was assigned as thymidine-3-mercaptocarbamic acid and is reported here as a new natural product.

Compound **4** ([Figure 1](#marinedrugs-17-00584-f001){ref-type="fig"}) was purified as a white powder with molecular formula of C~10~H~15~N~3~O~5~S as established by the HRESIMS pseudomolecular ion peak at *m/z* 290.0812 \[M + H\]^+^, being 44 mass unit less than **3**. Comparison of the ^1^H and ^13^C NMR data of **4** with those of **3** ([Table 4](#marinedrugs-17-00584-t004){ref-type="table"} and [Figures S23 and S24](#app1-marinedrugs-17-00584){ref-type="app"}) displayed identical signals, suggesting similar structures of both compounds. The protonated and quaternary carbons were assigned from 2D NMR experiments including COSY, HSQC and HMBC experiments ([Figures S25--S27](#app1-marinedrugs-17-00584){ref-type="app"}). The loss of 44 mass unit in **4** suggested the absence of the COOH moiety ([Table 4](#marinedrugs-17-00584-t004){ref-type="table"}). The presence of a thiohydroxylamine moiety in **4** was also supported by MS/MS fragmentation ion peaks at *m/z* 273 \[M − NH~2~\]^+^ and 242 \[M − SNH~2~ + H\]^+^ ([Figure 7](#marinedrugs-17-00584-f007){ref-type="fig"} and [Figure 8](#marinedrugs-17-00584-f008){ref-type="fig"}), completing the planner structure of **4**. The configuration of the sugar moiety of **4** was established by comparison of the NMR data of **3** and **4** ([Table 3](#marinedrugs-17-00584-t003){ref-type="table"} and [Table 4](#marinedrugs-17-00584-t004){ref-type="table"}). In addition, both compounds displayed positive optical rotation values (+11° and +13°, respectively), supported the same *β* configuration of the sugar part and the [d]{.smallcaps}-nucleoside in both compounds. Therefore, **4** was assigned as thymidine-3-thioamine and is reported here as a new natural product. It is worth to mention that, the occurrence of the mercaptocarbamic acid and thiohydroxylamine moieties in **3** and **4** are presented here for the first time from a natural source.

Compounds **5** and **6** were identified by interpretation of their NMR ([Figures S29--S38](#app1-marinedrugs-17-00584){ref-type="app"}) and MS data as well as their optical rotations and by comparison with available data in the literature. The absolute configuration of the amino acid moieties in **5** and **6** was determined by HPLC analysis of the derivatives of 1-fluoro-2,4-dinitrophenyl-5-[l]{.smallcaps}-alanine amide (FDAA, Marfey's reagent) with the hydrolytic products of **5--7** as previously reported \[[@B24-marinedrugs-17-00584]\]. Accordingly, the compounds were assigned as cyclo([d]{.smallcaps}-Pro-[l]{.smallcaps}-Phe) (**5**) \[[@B19-marinedrugs-17-00584]\] and cyclo([l]{.smallcaps}-Pro-[l]{.smallcaps}-Phe) (**6**) \[[@B20-marinedrugs-17-00584]\].

The compounds were evaluated for their cytotoxic activities in the sulforhodamine B (SRB) assay \[[@B30-marinedrugs-17-00584]\] against HCT-116 (colorectal carcinoma, ATCC CCL-247) and MCF-7 (breast cancer, ATCC HTB-22). Compound **5** showed moderate activity with IC~50~ of 32.7 µM against HCT-116, while other compounds were weakly active against this cell line. On the other hand, all compounds showed weak activities against breast cancer cell line ([Table 5](#marinedrugs-17-00584-t005){ref-type="table"}).

Furthermore, the antimicrobial activities of the compounds were evaluated against *S. aureus* and *C. albicans* using disc diffusion assay \[[@B31-marinedrugs-17-00584]\] at 100 μg/disc. Compounds **1** and **2** were potently active against *S. aureus* with inhibition zones of 23 and 20 mm, respectively, while these compounds displayed moderate activity against *C. albicans* with inhibition zones of 19 and 16 mm, respectively ([Table 5](#marinedrugs-17-00584-t005){ref-type="table"}). On the other hand, compounds **5** and **6** displayed moderate activity against *S. aureus* and *C. albicans* with inhibition zones of 9.0--14.0 mm ([Table 5](#marinedrugs-17-00584-t005){ref-type="table"}).

As a result, the moderate cytotoxicity of **5** and the weak cytotoxicity of other diketopiperazines (**1**, **2**, and **6**) may suggest the need to screen these compounds against a variety of other cell lines or completely different biological target. Moreover, the strong antimicrobial activities of **1** and **2** support the use of such compounds as a template or scaffold to develop structurally related antimicrobial drugs.

3. Materials and Methods {#sec3-marinedrugs-17-00584}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-17-00584}
------------------------------------

Optical rotations were measured on a JASCO DIP-370 digital polarimeter at 25 °C at the sodium D line (589 nm). UV spectra were recorded on a Hitachi 300 spectrometer (Hitachi High-Technologies Corporation, Kyoto, Japan). The ECD spectra were obtained on a JASCO J-810 spectropolarimeter with a 0.5 cm cell in MeOH. IR spectra were measured on a Shimadzu Infrared-400 spectrophotometer (Shimadzu, Kyoto, Japan). 1D and 2D NMR spectra (chemical shifts in ppm, coupling constants in Hz) were recorded on Bruker Avance DRX 600 MHz (600 MHz for ^1^H and 150 MHz for ^13^C NMR) (Bruker, Rheinstetten, Germany) and Bruker Ascend™ 850 MHz (850 MHz for ^1^H and 213 MHz for ^13^C NMR) (Bruker BioSpin, Billerica, MA, USA) spectrometers using CDCl~3~ or DMSO-*d*~6~ as solvent. NMR spectra were referenced to the residual protonated solvent signals (for CHCl~3~: 7.26 ppm for ^1^H and 77.0 ppm for ^13^C; for DMSO: 2.51 ppm for ^1^H and 39.6 ppm for ^13^C). Positive ion HRESIMS data were obtained with a Micromass Q-ToF equipped with leucine enkaphalin lockspray, using *m*/*z* 556.2771 \[M + H\]^+^ as a reference mass. For column chromatography, silica gel (Merck, 70-230 mesh ASTM) and Sephadex LH-20 (0.25--0.1 mm, Pharmacia) were used. Precoated silica gel 60 F-254 plates (Merck) were used for TLC. HPLC purifications were performed on a semi-preparative HPLC column (RP18, 5 μm, ARII Cosmosil, 250 × 10 mm, Waters).

3.2. Biological Materials {#sec3dot2-marinedrugs-17-00584}
-------------------------

The actinomycete *Streptomyces* species Call-36 was isolated from the Red Sea sponge *Callyspongia* species. To purify the actinomycete strain from the sponge materials, the previously reported protocol from our laboratory was used \[[@B16-marinedrugs-17-00584]\]. Identification of the actinomycete strain was based on 16S rRNA gene sequence analysis. Purification of the genomic DNA, the amplification of the 16S rRNA gene by PCR, and sequence alignment of the strain were performed as reported before \[[@B32-marinedrugs-17-00584]\]. The 16S rRNA gene sequence of the strain displayed 99% similarity with type strains of *Streptomyces albus* subsp. *albus* (AB184781) and *Streptmyces almquistii* (AB184258).

3.3. Fermentation and Extraction {#sec3dot3-marinedrugs-17-00584}
--------------------------------

The spores of *Streptomyces* sp. Call-36 were cultured in Erlenmeyer flasks (2 L) containing 500 mL of ISP-2 fermentation media. The media contained 4.0 g of yeast extract, 10 g of malt extract and 4.0 g of dextrose and 3.3% sea salt in 1 L distilled water (pH 7.2). The cultures were incubated on a rotatory shaker at 180 rpm at 28 °C for 15 days. The combined fermentation broths (10 L) were partitioned against EtOAc and the resulting EtOAc solutions were concentrated under vacuum to give a brown residue (2.4 g).

3.4. Purification of the Compounds {#sec3dot4-marinedrugs-17-00584}
----------------------------------

The EtOAc extract (2.4 g) was subjected to SiO~2~ VLC using n-hexane/CH~2~Cl~2~/MeOH gradients to give five fractions (A--E). Fraction C (370 mg) was purified by gel filtration over Sephadex LH-20 with MeOH to give four subfractions (C1-C4). Fraction C2 (120 mg) was purified on C18 HPLC column with 40% CH~3~CN to yield **1** (3.5 mg) and **2** (2.3 mg). Fraction C4 (60 mg) was purified on C18 HPLC column with 30% CH~3~CN to yield **3** (1.8 mg) and **4** (1.5 mg). Fraction D (410 mg) was purified by gel filtration over Sephadex LH-20 with MeOH to give five subfractions (D1-D5). Fraction D3 (110 mg) was further purified on C18 HPLC column with 40% CH~3~CN to yield **5** (2.5 mg) and **6** (3.6 mg).

3.5. Spectral Data of the Compounds {#sec3dot5-marinedrugs-17-00584}
-----------------------------------

Actinozine A (**1**): colorless solid; \[α\]~D~ −52° (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*): 230 (4.15), 303 (4.09) nm; ECD (MeOH) \[Δε\]~203nm~ −15.40, \[Δε\]~224nm~ +13.27; IR (film) *ν*~max~ 3450, 1656, 1627 cm^−1^; NMR data: [Table 1](#marinedrugs-17-00584-t001){ref-type="table"}; HRESIMS *m*/*z* 243.1344 (calcd for C~11~H~19~N~2~O~4~, \[M + H\]^+^, 243.1345).

Cyclo(2-OH-[d]{.smallcaps}-Pro-[l]{.smallcaps}-Leu) (**2**): colorless oil; \[α\]~D~ −50° (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*): 231 (4.17), 305 (4.00) nm; ECD (MeOH) \[Δε\]~203nm~ −30.25, \[Δε\]~223nm~ +29.82; IR (film) *ν*~max~ 3445, 1659, 1628 cm^−1^; NMR data: [Table 2](#marinedrugs-17-00584-t002){ref-type="table"}; HRESIMS *m*/*z* 227.1395 (calcd for C~11~H~19~N~2~O~3~, \[M + H\]^+^, 227.1396).

Thymidine-3-mercaptocarbamic acid (**3**): white solid; \[α\]~D~ +11° (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*): 265 (3.45), 255 (3.50) nm; NMR data: [Table 3](#marinedrugs-17-00584-t003){ref-type="table"}; HRESIMS *m*/*z* 334.0708 (calcd for C~11~H~16~N~3~O~7~S, \[M + H\]^+^, 334.0709).

Thymidine-3-thioamine (**4**): white solid; \[α\]~D~ +13° (*c* 0.1, MeOH); UV (MeOH *λ*~max~ (log *ε*): 266 (3.50), 256 (3.55) nm; NMR data: [Table 3](#marinedrugs-17-00584-t003){ref-type="table"}; HRESIMS *m*/*z* 290.0812 (calcd for C~10~H~16~N~3~O~5~S, \[M + H\]^+^, 290.0811).

3.6. Determination of the Configuration of the Leucine Moiety in **1** and **2** {#sec3dot6-marinedrugs-17-00584}
--------------------------------------------------------------------------------

Compounds **1** and **2** (each about 0.5 mg) were heated separately in 1 mL of 6 N HCl at 100 °C for 16 h, followed by removal of the excess HCl under vacuum. To each dry hydrolysate, 200 µL of 1% solution of 1-fluoro-2,4-dinitrophenyl-5-[l]{.smallcaps}-alanine amide (FDAA, Marfey's reagent) \[[@B24-marinedrugs-17-00584]\] in acetone and 40 µL of 1.0 M NaHCO~3~ were added. The reaction mixture was heated at 45 °C for 1.5 h, cooled, and acidified with 20 µL of 2.0 M HCl. Similarly, standard amino acids ([d]{.smallcaps} and [l]{.smallcaps}) of phenylalanine and leucine were derivatized separately. The derivatized standard amino acids and hydrolysates of **1** and **2** were subjected to HPLC on Nova-Pak C18 reverse-phase column (150 × 3.9 mm i.d., 4 mm particle size; Waters, Milford, MA, USA) using the following gradient program. Solvent A was a 50 mM triethylamine--phosphate buffer (pH 3.5) containing 25% (v/v) MeOH, and solvent B was the same buffer containing 70% MeOH. The mobile phase was a linear gradient from 0 to 100% B (100 to 0% A) in 40 min, at a flow rate of 0.65 mL/min at 25 °C. The eluted peaks were monitored at 340 nm. The retention times for FDAA derivatives of standards and compounds **1** and **2** were as follows: ([l]{.smallcaps})-leucine (*t*~R~ 27.2 min), ([d]{.smallcaps})-leucine (*t*~R~ 36.0 min), compound **1** (*t*~R~ 27.2 min) and compound **2** (*t*~R~ 27.2 min) ([Figure S39](#app1-marinedrugs-17-00584){ref-type="app"}).

3.7. Computational Details {#sec3dot7-marinedrugs-17-00584}
--------------------------

All DFT calculations have been performed using Gaussian 16 \[[@B33-marinedrugs-17-00584]\]. A conformation analysis was conducted using the GMMX plugin followed by a geometry optimization at the B3LYP/6-31g(d) level. A frequency check was performed at the same level of theory. GIAO NMR properties were calculated at the mpw1pw91/6-311+g(2d,p) level. DP4 probabilities were calculated using our own implementation of the algorithm published by Smith and Goodman \[[@B21-marinedrugs-17-00584]\]. Rotational strengths were calculated on 20 excited states using the b3lyp/6-31g(d) level of theory. The ECD spectra were plotted using Gaussview 6. All calculations for both isomers of **1** and **2** (3S,6S and 3R,6R) can be found at (<https://figshare.com/s/d626b72364548b03e11b>).

3.8. Cytotoxicity Evaluation {#sec3dot8-marinedrugs-17-00584}
----------------------------

The cytotoxicity of the compounds was evaluated against three tumorous human cell lines including colorectal carcinoma (HCT-116, ATCC CCL-247) and breast cancer (MCF-7, ATCC HTB-22) ([Figure S40](#app1-marinedrugs-17-00584){ref-type="app"}). The evaluation of the cytotoxicity of the compounds was carried out by sulforhodamine B (SRB) assay as reported before \[[@B30-marinedrugs-17-00584]\].

3.9. Antimicrobial Evaluation {#sec3dot9-marinedrugs-17-00584}
-----------------------------

A disc diffusion assay was used to determine the antimicrobial activity of the compounds \[[@B31-marinedrugs-17-00584]\] with replication (*n* = 3). *Staphylococcus aureus* and *Candida albicans* served as target models for bacteria and fungi. A total of 100 µg of each compound was loaded onto 6-mm sterile circular filter-paper discs. The paper discs were left to air-dry. The dried paper discs were placed onto nutrient agar plates that had already been inoculated with a lawn of target microorganisms. After 24 h of incubation, the antimicrobial activity of the compounds was calculated.

4. Conclusions {#sec4-marinedrugs-17-00584}
==============

In conclusion, investigation of a sponge-derived actinomycete, *Streptomyces* sp. Call-36, yielded a new diketopiperazine alkaloid, actinozine A (**1**), with a hydroperoxy functionality at C-2 of the proline moiety, two new thymidine derivatives, thymidine-3-mercaptocarbamic acid (**3**) and thymidine-3-thioamine (**4**), with unprecedented functionalities at *N*-3 of the thymine moiety. Additionally, the previously reported compounds cyclo(2-OH-[d]{.smallcaps}-Pro-[l]{.smallcaps}-Leu) (**2**), cyclo([d]{.smallcaps}-Pro-[l]{.smallcaps}-Phe) (**5**) and cyclo([l]{.smallcaps}-Pro-[l]{.smallcaps}-Phe) (**6**) were isolated. The one- and two-dimensional NMR data and MS spectral determinations supported the assignment of the compounds. The absolute stereochemistry of **1** and **2** were established by Marfey's method and by comparison of the experimental and TDDFT-calculated ECD spectra with the experimental ones. Compounds **1** and **2** displayed potent activity against *S. aureus* and were moderately active against *C. albicans*. Finally, compound **5** displayed moderate and selective activity against HCT-116 with an IC~50~ of 32.7 μM.
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marinedrugs-17-00584-t001_Table 1

###### 

NMR data of compound **1** (600 and 150 MHz, CDCl~3~).

  ------------------------------------------------------------------------------
  No.        δ~C~ (mult.)   δ~H~ \[mult., *J* (Hz)\]      HMBC
  ---------- -------------- ----------------------------- ----------------------
  2          168.0, qC                                    

  3          56.0, CH       4.04 (dt, 7.2, 3.0)           C-2, C-5, C-10, C-11

  4 (N*H*)   \-             6.25 (brs)                    

  5          167.2, qC                                    

  6          95.5, qC                                     

  7          33.4, CH~2~    2.44 (ddd, 13.2, 7.2, 3.0)\   C-6, C-8, C-9
                            2.15 (m)                      

  8          19.2, CH~2~    2.16 (m), 2.08 (m)            C-6, C-7, C-9

  9          45.3, CH~2~    3.90 (ddd, 12.0, 8.6, 7.8)\   C-2, C-7, C-8
                            3.62 (ddd, 12.0, 9.6, 4.2)    

  10         44.1, CH~2~    1.96 (m), 1.84 (t, 7.2)       C-2, C-3, C-12, C-13

  11         24.5, CH       1.80 (nonet, 6.6)             C-3, C-12, C-13

  12         23.1, CH~3~    0.99 (d, 6.6)                 C-10, C-11

  13         21.1, CH~3~    0.95 (d, 6.6)                 C-10, C-11

  OO*H*                     9.27 (brs)                    
  ------------------------------------------------------------------------------

marinedrugs-17-00584-t002_Table 2

###### 

NMR data of compound **2** (600 and 150 MHz, CDCl~3~).

  ---------------------------------------------------------------------------
  No.        δ~C~ (mult.)   δ~H~ \[mult., *J* (Hz)\]   HMBC
  ---------- -------------- -------------------------- ----------------------
  2          168.0, qC                                 

  3          56.4, CH       3.97 (td, 10.4, 4.2)       C-2, C-5, C-10, C-11

  4 (N*H*)   \-             6.02 (brs)                 

  5          167.2, qC                                 

  6          86.7, qC                                  

  7          37.6, CH~2~    2.30 (m), 2.15 (m)         C-6, C-8, C-9

  8          19.2, CH~2~    2.18 (m), 2.08 (m)         C-6, C-7, C-9

  9          45.6, CH~2~    3.73 (m), 3.66 (m)         C-2, C-7, C-8

  10         44.4, CH~2~    1.88 (dd, 10.2, 7.2)\      C-2, C-3, C-12, C-13
                            1.80 (m)                   

  11         24.5, CH       1.80 (m)                   C-3, C-12, C-13

  12         23.0, CH~3~    1.00 (d, 6.0)              C-10, C-11

  13         21.2, CH~3~    0.94 (d, 6.0)              C-10, C-11

  O*H*                      2.97 (brs)                 
  ---------------------------------------------------------------------------

marinedrugs-17-00584-t003_Table 3

###### 

NMR data of compound **3** (600 and 150 MHz, DMSO-*d*~6~).

  -----------------------------------------------------------------------------------------------------------------
  No.              δ~C~ (mult.)   δ~H~ \[m., *J* (Hz)\]   HMBC                   ROESY
  ---------------- -------------- ----------------------- ---------------------- ----------------------------------
  2                150.4, qC      \-                                             

  4                163.7, qC      \-                                             

  5                109.3, qC      \-                                             

  6                136.1, CH      7.68 (s)                C-2, C-4, C-7          H~3~-7, H-1′, H-2′a, H-4′, H-5′a

  7                12.2, CH~3~    1.75 (s)                C-4, C-5, C-6          H-6

  1′               83.7, CH       6.15 (t, 7.0)           C-2, C-6, C-2′, C-3′   H-2′a, H-4′, H-6

  2′a\             39.5, CH~2~    2.07 (m)\               C-4′                   H-1′, H-6\
  2′b                             2.02 (m)                                       H-3′, H-4′, H-5′b

  3′               70.3, CH       4.22 (quin, 3.0)        C-1′, C-5′             H-2′b

  4′               87.2, CH       3.74 (q, 3.5)                                  H-2′b, H-5′a, H-6

  5′a\             61.3, CH~2~    3.57 (dd, 12.0, 3.5)\   C-3′                   H-4′, H-6\
  5′b                             3.53 (dd, 12.0,4.0)                            H-2′b

  O*H*-3′                         5.24 (brs)                                     

  O*H*-5′                         5.05 (brs)                                     

  N*H*                            7.26 (brs)                                     

  3′′ (*C*OO*H*)   158.1, qC      10.90 (hump)                                   
  -----------------------------------------------------------------------------------------------------------------

marinedrugs-17-00584-t004_Table 4

###### 

NMR data of compound **4** (850 and 213 MHz, DMSO-*d*~6~).

  -----------------------------------------------------------------------------
  No.       δ~C~ (mult.)   δ~H~ \[m., *J* (Hz)\]         HMBC
  --------- -------------- ----------------------------- ----------------------
  2         150.4, qC      \-                            

  4         163.7, qC      \-                            

  5         109.3, qC      \-                            

  6         136.1, CH      7.70 (s)                      C-2, C-4, C-7

  7         12.2, CH~3~    1.77 (s)                      C-4, C-5, C-6

  1′        83.7, CH       6.16 (t, 6.8)                 C-2, C-6, C-2′, C-3′

  2′a\      39.5, CH~2~    2.09 (ddd, 13.6, 7.7, 6.0)\   C-4′
  2′b                      2.04 (ddd, 13.6, 6.0, 3.4)    

  3′        70.4, CH       4.24 (m)                      C-1′, C-5′

  4′        87.2, CH       3.76 (q, 4.2)                 

  5′a\      61.3, CH~2~    3.58 (brd, 12.0)\             C-3′
  5′b                      3.54 (brd, 12.0)              

  O*H*-3′                  5.26 (brs)                    

  O*H*-5′                  5.06 (brs)                    

  N*H~2~*                  ^a^                           
  -----------------------------------------------------------------------------

^a^ Not observed.

marinedrugs-17-00584-t005_Table 5

###### 

Cytotoxic and antimicrobial activities of compounds **1**--**6**.

                      IC~50~ (μM)   Inhibition Zones (mm) at 100 μg/disc          
  ------------------- ------------- -------------------------------------- ------ ------
  1                   146           88.8                                   23.0   19.0
  2                   150           117                                    20.0   16.0
  3                   ≥50           90                                     NT     NT
  4                   ≥50           112                                    NT     NT
  5                   32.7          81.9                                   14.0   11.0
  6                   131           123                                    10.0   9.0
  Doxorubicin ^a^     1.62          0.77                                          
  Ciprofloxacin ^b^                                                        22.0   
  Ketoconazole ^c^                                                                30.0

NT = Not tested; ^a^ Positive cytotoxicity control; ^b^ Positive antibacterial control (5.0 µg/disc); ^c^ Positive antifungal control (50 µg/disc).
